EGFR and non-small cell lung carcinoma: Osimertinib, a third‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI), is the standard of care for EGFR mutation‐positive non‐small cell lung cancer (NSCLC).